Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 8 studies | 17% ± 2% | |
fibroblast | 7 studies | 22% ± 6% | |
endothelial cell | 5 studies | 26% ± 6% | |
myofibroblast cell | 4 studies | 19% ± 3% | |
pericyte | 4 studies | 21% ± 5% | |
epithelial cell | 4 studies | 33% ± 13% | |
neuron | 4 studies | 26% ± 12% | |
hematopoietic precursor cell | 3 studies | 24% ± 3% | |
neural crest cell | 3 studies | 18% ± 2% | |
ciliated cell | 3 studies | 27% ± 3% | |
macrophage | 3 studies | 19% ± 5% | |
dendritic cell | 3 studies | 25% ± 3% | |
glutamatergic neuron | 3 studies | 31% ± 11% | |
interneuron | 3 studies | 29% ± 13% | |
oligodendrocyte | 3 studies | 23% ± 1% | |
connective tissue cell | 3 studies | 24% ± 5% | |
oligodendrocyte precursor cell | 3 studies | 21% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
uterus | 100% | 1182.05 | 170 / 170 | 100% | 60.15 | 459 / 459 |
brain | 100% | 1196.45 | 2641 / 2642 | 100% | 67.65 | 705 / 705 |
prostate | 100% | 790.33 | 245 / 245 | 100% | 44.11 | 501 / 502 |
ovary | 100% | 1004.99 | 180 / 180 | 100% | 30.88 | 429 / 430 |
breast | 100% | 1005.49 | 459 / 459 | 100% | 48.27 | 1115 / 1118 |
thymus | 100% | 829.17 | 652 / 653 | 100% | 46.85 | 604 / 605 |
lung | 100% | 727.34 | 576 / 578 | 100% | 36.53 | 1155 / 1155 |
adrenal gland | 100% | 953.93 | 258 / 258 | 100% | 54.17 | 229 / 230 |
liver | 100% | 489.62 | 225 / 226 | 100% | 27.33 | 406 / 406 |
esophagus | 100% | 975.87 | 1445 / 1445 | 99% | 24.70 | 182 / 183 |
kidney | 100% | 730.36 | 89 / 89 | 99% | 32.35 | 896 / 901 |
bladder | 100% | 943.57 | 21 / 21 | 99% | 41.28 | 499 / 504 |
pancreas | 98% | 467.55 | 323 / 328 | 100% | 32.92 | 178 / 178 |
intestine | 100% | 988.51 | 966 / 966 | 98% | 28.87 | 518 / 527 |
stomach | 100% | 710.11 | 359 / 359 | 98% | 26.14 | 280 / 286 |
skin | 100% | 957.31 | 1807 / 1809 | 98% | 45.69 | 461 / 472 |
adipose | 100% | 1007.34 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 52.54 | 29 / 29 |
spleen | 100% | 923.74 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 52.31 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.47 | 1 / 1 |
blood vessel | 100% | 1182.83 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 675.28 | 798 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 697.85 | 846 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 21.59 | 75 / 80 |
peripheral blood | 62% | 407.69 | 579 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0140861 | Biological process | DNA repair-dependent chromatin remodeling |
GO_0006974 | Biological process | DNA damage response |
GO_0010835 | Biological process | regulation of protein ADP-ribosylation |
GO_0006281 | Biological process | DNA repair |
GO_0006302 | Biological process | double-strand break repair |
GO_0090734 | Cellular component | site of DNA damage |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0072572 | Molecular function | poly-ADP-D-ribose binding |
GO_0005515 | Molecular function | protein binding |
GO_0042393 | Molecular function | histone binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0140768 | Molecular function | protein ADP-ribosyltransferase-substrate adaptor activity |
Gene name | HPF1 |
Protein name | Histone PARylation factor 1 |
Synonyms | C4orf27 |
Description | FUNCTION: Cofactor for serine ADP-ribosylation that confers serine specificity on PARP1 and PARP2 and plays a key role in DNA damage response . Initiates the repair of double-strand DNA breaks: recruited to DNA damage sites by PARP1 and PARP2 and switches the amino acid specificity of PARP1 and PARP2 from aspartate or glutamate to serine residues, licensing serine ADP-ribosylation of target proteins . Serine ADP-ribosylation of target proteins, such as histones, promotes decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks . Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage . HPF1 acts by completing the active site of PARP1 and PARP2: forms a composite active site composed of residues from HPF1 and PARP1 or PARP2 . While HPF1 promotes the initiation of serine ADP-ribosylation, it restricts the polymerase activity of PARP1 and PARP2 in order to limit the length of poly-ADP-ribose chains . HPF1 also promotes tyrosine ADP-ribosylation, probably by conferring tyrosine specificity on PARP1 . . |
Accessions | ENST00000393381.3 Q9NWY4 |